Harry Dolstra

List of Publications by Year
in descending order

119 papers	5,800 citations	66343 42 h-index	88630 70 g-index
127 all docs	127 docs citations	127 times ranked	7612 citing authors

#	Article	IF	Citations
1	The first steps towards a diverse and inclusive EBMT: a position paper. Bone Marrow Transplantation, 2022, 57, 343-346.	2.4	2
2	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. Frontiers in Immunology, 2022, 13, 734256.	4.8	2
3	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 2022, 57, 742-752.	2.4	45
4	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation, 2022, 57, 1217-1239.	2.4	119
5	A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia, 2021, 35, 1586-1596.	7.2	57
6	IL-15 superagonist N-803 improves IFNÎ³ production and killing of leukemia and ovarian cancer cells by CD34+â€‰progenitor-derived NK cells. Cancer Immunology, Immunotherapy, 2021, 70, 1305-1321.	4.2	27
7	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 2021, 56, 1651-1664.	2.4	221
8	Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer Immunology, Immunotherapy, 2021, 70, 3167-3181.	4.2	13
9	Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nature Communications, 2021, 12, 5217.	12.8	99
10	CD34 ⁺ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg ^{null} mice. OncoImmunology, 2021, 10, 1981049.	4.6	13
11	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy, 2020, 22, 388-397.	0.7	29
12	TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. OncoImmunology, 2020, 9, 1843247.	4.6	48
13	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation, 2020, 55, 2071-2076.	2.4	163
14	PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. Bone Marrow Transplantation, 2020, 55, 2308-2318.	2.4	12
15	Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. Cancer Immunology, Immunotherapy, 2020, 69, 2259-2273.	4.2	4
16	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Tâ€™s come into focus. Bone Marrow Transplantation, 2020, 55, 1604-1613.	2.4	147
17	Harnessing natural killer cells for the treatment of ovarian cancer. Gynecologic Oncology, 2020, 157, 810-816.	1.4	43
18	Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease. ELife, 2020, 9, .	6.0	23

#	Article	IF	Citations
19	MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opinion on Biological Therapy, 2019, 19, 721-733.	3.1	43
20	CXCR4, but not CXCR3, drives CD8⁺ Tâ€cell entry into and migration through the murine bone marrow. European Journal of Immunology, 2019, 49, 576-589.	2.9	44
21	Peptide-mediated delivery of therapeutic mRNA in ovarian cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 180-190.	4.3	62
22	Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). Medicine (United States), 2019, 98, e14290.	1.0	20
23	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. Cancer Immunology Research, 2019, 7, 150-161.	3.4	29
24	Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 712-719.	2.0	28
25	Comprehensive Phenotyping of T Cells Using Flow Cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 647-654.	1.5	133
26	Immune checkpoint molecules in acute myeloid leukaemia: managing the doubleâ€edged sword. British Journal of Haematology, 2018, 181, 38-53.	2.5	42
27	Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 666-677.	2.0	45
28	Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice. Blood, 2018, 131, 202-214.	1.4	40
29	Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. OncoImmunology, 2018, 7, e1488565.	4.6	41
30	Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. Nature Communications, 2018, 9, 3317.	12.8	116
31	CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia. Blood, 2018, 132, 1454-1454.	1.4	8
32	Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. Oncotarget, 2018, 9, 34810-34820.	1.8	44
33	Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clinical Cancer Research, 2017, 23, 4107-4118.	7.0	139
34	Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responsesex vivo. OncoImmunology, 2017, 6, e1285991.	4.6	20
35	Association of MicroRNAâ€618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 1891-1902.	5.6	67
36	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. Cancer Immunology Research, 2017, 5, 710-715.	3.4	36

#	Article	IF	Citations
37	A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. Bone Marrow Transplantation, 2017, 52, 1378-1383.	2.4	21
38	Umbilical cord blood CD34⁺progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rg^{null}mice. OncoImmunology, 2017, 6, e1320630.	4.6	50
39	CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. Journal of Immunology, 2016, 197, 2715-2725.	0.8	43
40	The magnitude of cytokine production by stimulated CD56+ cells is associated with early stages of systemic sclerosis. Clinical Immunology, 2016, 173, 76-80.	3.2	23
41	Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses. Biology of Blood and Marrow Transplantation, 2016, 22, 1000-1008.	2.0	42
42	LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application. Haematologica, 2015, 100, e419-e422.	3.5	14
43	Efficient Nontoxic Delivery of PD-L1 and PD-L2 siRNA Into Dendritic Cell Vaccines Using the Cationic Lipid SAINT-18. Journal of Immunotherapy, 2015, 38, 145-154.	2.4	39
44	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Antiâ€“PD-L1 Antibodies. Cancer Research, 2015, 75, 2928-2936.	0.9	193
45	The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34⁺Hematopoietic Stem and Progenitor Cells. Stem Cells and Development, 2015, 24, 2886-2898.	2.1	29
46	Combined IL-15 and IL-12 drives the generation of CD34⁺-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. OncoImmunology, 2015, 4, e1017701.	4.6	44
47	Umbilical cord bloodâ€“derived cellular products for cancer immunotherapy. Cytotherapy, 2015, 17, 739-748.	0.7	22
48	siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg(null) mice. Cancer Immunology, Immunotherapy, 2015, 64, 645-654.	4.2	42
49	The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Bone Marrow Transplantation, 2015, 50, 822-828.	2.4	17
50	Time toAkt. OncoImmunology, 2015, 4, e1003016.	4.6	3
51	A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients. Blood, 2015, 126, 1357-1357.	1.4	31
52	Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 31-58.	0.1	0
53	Functionally active NKG2A-expressing natural killer cells are elevated in rheumatoid arthritis patients compared to psoriatic arthritis patients and healthy donors. Clinical and Experimental Rheumatology, 2015, 33, 795-804.	0.8	3
54	Immunotherapeutic approaches to treat multiple myeloma. Human Vaccines and Immunotherapeutics, 2014, 10, 896-910.	3.3	7

#	Article	IF	Citations
55	Ex Vivo Generation of Interstitial and Langerhans Cell-like Dendritic Cell Subsetâ€“based Vaccines for Hematological Malignancies. Journal of Immunotherapy, 2014, 37, 267-277.	2.4	9
56	Targeting the IL17 Pathway for the Prevention of Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 752-759.	2.0	36
57	The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34⁺ Hematopoietic Progenitor Cells. Stem Cells and Development, 2014, 23, 955-967.	2.1	53
58	Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood, 2014, 124, 3490-3500.	1.4	103
59	The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1 Stimulates Expression of NK Cell Related Transcription Factors, Thereby It Facilitates Generation of Highly Functional NK Cells in Vitro. Blood, 2014, 124, 3833-3833.	1.4	1
60	Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunology, Immunotherapy, 2013, 62, 1381-1392.	4.2	61
61	Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1244-1253.	2.0	93
62	Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunology, Immunotherapy, 2013, 62, 285-297.	4.2	111
63	Homing Characteristics of Donor T Cells after Experimental Allogeneic Bone Marrow Transplantation and Posttransplantation Therapy for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 378-386.	2.0	10
64	Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 274-282.	2.0	43
65	Gender influences the birth order effect in HLA-identical stem cell transplantation. Blood, 2013, 121, 4809-4811.	1.4	1
66	Induction of myelodysplasia by myeloid-derived suppressor cells. Journal of Clinical Investigation, 2013, 123, 4595-4611.	8.2	254
67	Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice. PLoS ONE, 2013, 8, e64384.	2.5	71
68	Akt Signalling Inhibition Promotes The Ex Vivo generation Of Minor Histocompatibility Antigen-Specific CD8+ Memory Stem T Cells. Blood, 2013, 122, 3269-3269.	1.4	0
69	B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation. Journal of Immunology, 2012, 189, 39-49.	0.8	60
70	Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs. Bone Marrow Transplantation, 2012, 47, 1229-1234.	2.4	5
71	Ex Vivo Generated Natural Killer Cells Acquire Typical Natural Killer Receptors and Display a Cytotoxic Gene Expression Profile Similar to Peripheral Blood Natural Killer Cells. Stem Cells and Development, 2012, 21, 2926-2938.	2.1	26
72	Natural Killer Cell Differentiation from Hematopoietic Stem Cells: A Comparative Analysis of Heparin- and Stromal Cellâ€“Supported Methods. Biology of Blood and Marrow Transplantation, 2012, 18, 536-545.	2.0	29

#	Article	IF	Citations
73	Defining Early Human NK Cell Developmental Stages in Primary and Secondary Lymphoid Tissues. PLoS ONE, 2012, 7, e30930.	2.5	69
74	Decreased Levels of Circulating IL17-Producing CD161+CCR6+ T Cells Are Associated with Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. PLoS ONE, 2012, 7, e50896.	2.5	39
75	Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood, 2012, 120, 728-736.	1.4	69
76	Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation. Bio-protocol, 2012, 2, .	0.4	0
77	Polymorphisms in CCR6 Are Associated with Chronic Graft-versus-Host Disease and Invasive Fungal Disease in Matched-Related Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1443-1449.	2.0	15
78	Concurrent Detection of Circulating Minor Histocompatibility Antigen-Specific CD8+ T Cells in SCT Recipients by Combinatorial Encoding MHC Multimers. PLoS ONE, 2011, 6, e21266.	2.5	6
79	A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR. PLoS ONE, 2011, 6, e21699.	2.5	24
80	T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C andÂNKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines. Experimental Hematology, 2011, 39, 751-762.e3.	0.4	15
81	Extensive natural killer cell receptor phenotyping on NK and T cells discloses differences in RA and PsA, potentially mirroring diverse immunoregulatory functions. Journal of Translational Medicine, 2011, 9, P42.	4.4	0
82	PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation. Cancer Research, 2011, 71, 5111-5122.	0.9	140
83	Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process. PLoS ONE, 2011, 6, e20740.	2.5	199
84	CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia, 2010, 24, 583-591.	7.2	26
85	An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells. Journal of Leukocyte Biology, 2010, 87, 1029-1039.	3.3	29
86	siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigenâ€“specific CD8+ T cells. Blood, 2010, 116, 4501-4511.	1.4	133
87	Partial T Cell-Depleted Allogeneic Stem Cell Transplantation following Reduced-Intensity Conditioning Creates a Platform for Immunotherapy with Donor Lymphocyte Infusion and Recipient Dendritic Cell Vaccination in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2010, 16, 320-332.	2.0	22
88	High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. PLoS ONE, 2010, 5, e9221.	2.5	150
89	Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis. Cancer Immunology, Immunotherapy, 2009, 58, 429-439.	4.2	15
90	NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2009, 44, 243-248.	2.4	57

#	Article	IF	Citations
91	Efficient Activation of LRH-1â€“specific CD8+ T-cell Responses From Transplanted Leukemia Patients by Stimulation With P2X5 mRNA-electroporated Dendritic Cells. Journal of Immunotherapy, 2009, 32, 539-551.	2.4	13
92	Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1â€“reactive cytotoxic T cells. Blood, 2009, 113, 2312-2323.	1.4	46
93	Intratumoral rhILâ€12 administration in head and neck squamous cell carcinoma patients induces B cell activation. International Journal of Cancer, 2008, 123, 2354-2361.	5.1	76
94	Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. British Journal of Haematology, 2008, 141, 799-807.	2.5	33
95	Refinement of molecular approaches to improve the chance of identification of hematopoietic-restricted minor histocompatibility antigens. Journal of Immunological Methods, 2008, 329, 125-137.	1.4	2
96	Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. Journal of Experimental Medicine, 2008, 205, 2863-2872.	8.5	59
97	Phenotype Frequencies of Autosomal Minor Histocompatibility Antigens Display Significant Differences among Populations. PLoS Genetics, 2007, 3, e103.	3.5	68
98	Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplantation, 2007, 40, 355-359.	2.4	23
99	Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. Bone Marrow Transplantation, 2007, 40, 585-592.	2.4	16
100	Aberrant Expression in Human Epithelial Cancers of the P2X5-Encoded Minor Histocompatibility Antigen LRH-1: Implications for Graft-Versus-Tumor Immunity Against Solid Tumors.. Blood, 2007, 110, 1795-1795.	1.4	0
101	Human CD34+ Myeloid Leukemic Progenitor Cells Are Susceptible to Lysis by Minor Histocompatibility Antigen LRH-1-Specific Cytotoxic T Lymphocytes.. Blood, 2006, 108, 134-134.	1.4	14
102	The Balance in Chimerism between T Cells and Blood Dendritic Cells in Relapsed CML Patients Influences the Induction of Alloreactivity Following Donor Lymphocyte Infusion.. Blood, 2006, 108, 5139-5139.	1.4	0
103	Vaccination with Host Dendritic Cells Induces Graft-Versus-Leukemia Responses without Severe Graft-Versus-Host Disease in a Preclinical Mouse Model for Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 3239-3239.	1.4	0
104	Use of RNA Electroporated DC for Activation of LRH-1 Specific Cytotoxic T Lymphocytes in the Treatment of Lymphoid Malignancies.. Blood, 2006, 108, 138-138.	1.4	1
105	Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Current Opinion in Oncology, 2005, 17, 617-621.	2.4	21
106	Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. British Journal of Haematology, 2005, 130, 852-859.	2.5	39
107	A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. Journal of Clinical Investigation, 2005, 115, 3506-3516.	8.2	142
108	A Novel Tissue-Restricted Minor Histocompatibility Antigen Resulting from Differential Expression Due to a Deletion/Insertion Polymorphism in the P2X5 Purinergic Receptor Gene.. Blood, 2004, 104, 3062-3062.	1.4	0

#	Article	IF	Citations
109	Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia, 2003, 17, 621-629.	7.2	80
110	Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia, 2003, 17, 630-633.	7.2	21
111	Monitoring of Developing Graft-Versus-Host Disease Mediated by Herpes Simplex Virus Thymidine Kinase Gene-Transduced T Cells. Human Gene Therapy, 2003, 14, 341-351.	2.7	5
112	Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemiaâ€“associated antigen HB-1: relevance for precursor B-ALLâ€“specific immunotherapy. Blood, 2003, 102, 2885-2891.	1.4	14
113	Biodistribution and Retention Time of Retrovirally Labeled T Lymphocytes in Mice is Strongly Influenced by the Culture Period Before Infusion. Journal of Immunotherapy, 2002, 25, 385-395.	2.4	10
114	Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. European Journal of Immunology, 2002, 32, 2748-2758.	2.9	55
115	TCRÎ³Î´ cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplantation, 2001, 27, 1087-1093.	2.4	51
116	A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia. Journal of Experimental Medicine, 1999, 189, 301-308.	8.5	207
117	Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. Journal of Immunology, 1997, 158, 560-5.	0.8	71
118	Expansion of CD8⁺CD57⁺ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. British Journal of Haematology, 1995, 90, 300-307.	2.5	60
119	Monochlorobimane Does Not Selectively Label Glutathione in Peripheral Blood Mononuclear Cells. Analytical Biochemistry, 1994, 217, 41-47.	2.4	32